EIGR - Eiger BioPharmaceuticals Inc Stock Price, Fair Value and News

2.43USD-0.17 (-6.54%)Delayed

Market Summary

USD2.43-0.17

Delayed

-6.54%

EIGR Stock Price

View Fullscreen

EIGR RSI Chart

EIGR Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-0.05

Price/Sales (Trailing)

0.25

EV/EBITDA

0.32

Price/Free Cashflow

-0.05

EIGR Price/Sales (Trailing)

EIGR Profitability

Operating Margin

99.83%

EBT Margin

-522.31%

Return on Equity

518.49%

Return on Assets

-193.07%

Free Cashflow Yield

-2.1K%

EIGR Fundamentals

EIGR Revenue

Revenue (TTM)

14.4M

Rev. Growth (Yr)

41.06%

Rev. Growth (Qtr)

18.51%

EIGR Earnings

Earnings (TTM)

-75.0M

Earnings Growth (Yr)

46.48%

Earnings Growth (Qtr)

25.38%

Breaking Down EIGR Revenue

Last 7 days

0.8%

Last 30 days

63.0%

Last 90 days

-58.7%

Trailing 12 Months

-92.2%

How does EIGR drawdown profile look like?

EIGR Financial Health

Current Ratio

0.71

EIGR Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-50.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	15.5M	14.6M	14.4M
2022	11.2M	13.2M	14.1M	13.5M
2021	0	0	0	12.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Eiger BioPharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 02, 2023	kayne richard a	bought	6,965	0.2977	23,398	-
Nov 01, 2023	kayne richard a	bought	27,970	0.2797	100,000	-
Oct 31, 2023	kayne richard a	bought	37,879	0.244636	154,841	-
Oct 31, 2023	kawas leen	bought	6,374	0.261993	24,332	-
Mar 17, 2023	mayer eldon c. iii	sold	-4,703	1.0703	-4,395	ex vp & chief commerc. officer
Jan 23, 2023	dietz thomas john	bought	71,580	1.4316	50,000	-
Dec 29, 2022	murray christine	sold	-6,104	1.2208	-5,000	-
Dec 22, 2022	dietz thomas john	sold	-26,302	1.169	-22,500	-
Dec 22, 2022	glenn jeffrey s	bought	127,950	1.2795	100,000	-
Aug 16, 2022	apelian david	sold	-49,030	9.8061	-5,000	-

Which funds bought or sold EIGR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Accretive Wealth Partners, LLC	new	-	169,874	169,874	0.07%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-652	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	470	470	-%
Apr 30, 2024	Sequoia Financial Advisors, LLC	sold off	-100	-14,144	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-4,634	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-2,000	-	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	56.00	56.00	-%

Are Funds Buying or Selling EIGR?

Are funds buying EIGR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EIGR

No. of Funds

Unveiling Eiger BioPharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ameriprise financial inc	16.91%	7,505,539	SC 13G/A
Feb 14, 2024	683 capital management, llc	4.7%	70,000	SC 13G/A
Dec 04, 2023	arkin moshe	10.09%	4,481,126	SC 13D/A
Nov 24, 2023	arkin moshe	10.09%	4,482,126	SC 13D
Nov 03, 2023	propel bio management, llc	9.91%	4,391,432	SC 13D/A
Oct 20, 2023	propel bio management, llc	9.86%	4,367,100	SC 13D
Sep 28, 2023	propel bio management, llc	10.9%	4,823,938	SC 13G/A
Aug 15, 2023	propel bio management, llc	5.40%	2,392,167	SC 13G
Jul 07, 2023	blackrock inc.	2.1%	937,125	SC 13G/A
Apr 18, 2023	arkin moshe	10.15%	4,482,126	SC 13G/A

Recent SEC filings of Eiger BioPharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 25, 2024	25-NSE	25-NSE
Apr 08, 2024	10-K	Annual Report
Apr 03, 2024	8-K	Current Report
Apr 01, 2024	S-8 POS	Employee Benefits Plan
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	NT 10-K	NT 10-K
Apr 01, 2024	S-8 POS	Employee Benefits Plan
Apr 01, 2024	S-8 POS	Employee Benefits Plan

Peers (Alternatives to Eiger BioPharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Eiger BioPharmaceuticals Inc News

Latest updates

Eiger BioPharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	18.5%	3,803,000	3,209,000	4,643,000	2,696,000	4,024,000	4,091,000	2,673,000	3,360,000	3,039,000	2,097,000	3,646,000
Cost Of Revenue	-100.0%	-	115,000	-	345,000	1,231,000	151,000	110,000	104,000	318,000	270,000	53,000
Costs and Expenses	-18.5%	16,417,000	20,137,000	24,624,000	27,167,000	30,393,000	24,171,000	24,493,000	24,274,000	24,890,000	20,458,000	19,459,000
S&GA Expenses	-13.8%	4,702,000	5,454,000	5,533,000	8,301,000	6,964,000	7,027,000	6,813,000	5,984,000	6,466,000	5,886,000	5,564,000
R&D Expenses	-20.3%	11,614,000	14,568,000	19,401,000	18,521,000	22,198,000	16,993,000	17,570,000	18,186,000	18,106,000	14,302,000	13,842,000
EBITDA Margin	13.3%	-4.82	-5.57	-5.86	-6.85	-6.31	-6.42	-7.33	-2.47	-	-	-
Interest Expenses	1.0%	1,426,000	1,412,000	1,343,000	1,220,000	1,092,000	934,000	886,000	900,000	894,000	880,000	885,000
Income Taxes	-	2,000	-	2,000	-3,000	-	17,000	9,000	18,000	16,000	11,000	19,000
Earnings Before Taxes	25.4%	-13,452,000	-18,030,000	-20,693,000	-25,141,000	-27,111,000	-21,867,000	-22,634,000	-21,750,000	-22,207,000	-19,163,000	29,267,000
EBT Margin	12.2%	-5.22	-5.95	-6.19	-7.18	-6.60	-6.72	-7.68	-2.79	-	-	-
Net Income	25.4%	-13,454,000	-18,030,000	-20,695,000	-25,138,000	-27,111,000	-21,884,000	-22,643,000	-21,768,000	-22,223,000	-19,174,000	29,248,000
Net Income Margin	12.2%	-5.22	-5.95	-6.19	-7.18	-6.60	-6.72	-7.68	-2.79	-	-	-
Free Cashflow	4.1%	-13,955,000	-14,554,000	-22,052,000	-22,471,000	-20,667,000	-21,753,000	-18,459,000	-16,898,000	-19,260,000	-20,460,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-30.2%	39.00	56.00	72.00	99.00	120	144	164	153	126	140	157	176	144	141	103	88.00	105	120	133	93.00	102
Current Assets	-30.7%	38.00	55.00	70.00	97.00	118	142	158	147	103	99.00	119	170	138	135	97.00	82.00	100	114	128	88.00	102
Cash Equivalents	-7.5%	25.00	28.00	23.00	15.00	26.00	26.00	37.00	47.00	22.00	49.00	65.00	108	29.00	52.00	63.00	23.00	39.00	19.00	58.00	63.00	61.00
Inventory	40.8%	2.00	1.00	1.00	5.00	3.00	3.00	3.00	2.00	3.00	3.00	2.00	1.00	0.00	-	-	-	-	-	-	-	-
Net PPE	-7.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Liabilities	-6.9%	53.00	57.00	57.00	64.00	65.00	65.00	61.00	56.00	54.00	51.00	48.00	49.00	49.00	48.00	45.00	45.00	49.00	48.00	45.00	42.00	36.00
Current Liabilities	222.5%	53.00	17.00	17.00	24.00	25.00	26.00	22.00	37.00	30.00	22.00	16.00	18.00	17.00	22.00	16.00	13.00	17.00	17.00	13.00	11.00	10.00
Long Term Debt	-100.0%	-	41.00	40.00	40.00	40.00	39.00	39.00	19.00	24.00	29.00	31.00	31.00	31.00	25.00	27.00	31.00	30.00	30.00	30.00	30.00	26.00
LT Debt, Current	-	41.00	-	-	-	-	-	-	13.00	8.00	3.00	-	-	-	6.00	3.00	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	41.00	40.00	40.00	40.00	39.00	39.00	19.00	24.00	29.00	31.00	31.00	31.00	25.00	27.00	31.00	30.00	30.00	30.00	30.00	26.00
Shareholder's Equity	-Infinity%	-14.46	-	15.00	35.00	55.00	78.00	103	97.00	72.00	89.00	109	126	95.00	93.00	58.00	43.00	56.00	72.00	88.00	51.00	67.00
Retained Earnings	-2.7%	-512	-498	-480	-459	-437	-412	-384	-363	-340	-318	-296	-277	-306	-287	-272	-256	-241	-224	-205	-188	-171
Additional Paid-In Capital	0.1%	498	497	496	495	493	491	489	461	413	408	406	403	402	381	330	300	298	296	294	239	238
Shares Outstanding	0.3%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	30.00	-	-	-	274	-	-	-	286	-	-	-	258	-	-	-	255	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.1%	-13,954	-14,554	-22,035	-24,005	-22,247	-20,560	-21,744	-18,459	-16,765	-19,260	-20,384	-14,933	-15,515	-14,108	-15,822	-17,740	-14,971	-14,591	-15,170	-18,882	-12,502
Share Based Compensation	-34.2%	683	1,038	745	2,542	1,840	2,222	2,208	2,047	1,964	2,330	2,058	1,549	1,437	1,445	1,462	1,629	1,348	1,649	1,487	1,195	1,511
Cashflow From Investing	-36.8%	11,999	19,000	29,846	13,383	21,797	10,384	-19,547	-3,002	-13,333	3,299	-22,898	94,464	-26,967	-45,429	26,957	652	34,619	-24,874	-43,072	16,856	9,070
Cashflow From Financing	-53.3%	7.00	15.00	-22.00	41.00	-60.00	-88.00	31,301	45,802	3,064	160	-72.00	15.00	19,353	48,717	29,049	344	319	450	53,256	4,171	47,767

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EIGR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Revenues [Abstract]

Total revenue

^[1]

$ 15,773,000

$ 13,484,000

Costs and operating expenses:

Cost of sales

^[1]

24,000

1,837,000

Research and development

^[1]

62,331,000

75,282,000

Selling, general and administrative

^[1]

25,204,000

29,105,000

Total costs and operating expenses

^[1]

87,559,000

106,224,000

Loss from operations

^[1]

(71,786,000)

(92,740,000)

Interest expense

^[1]

(5,466,000)

(4,132,000)

Interest income

^[1]

2,208,000

1,082,000

Other (expense) income, net

^[1]

87,000

(963,000)

Loss before provision for income taxes

^[1]

(74,957,000)

(96,753,000)

Provision for income taxes

^[1]

6,000

23,000

Net loss

$ (74,963,000)

^[1]

$ (96,776,000)

^[2]

Net loss per common share:

Basic (in USD per share)

^[1]

$ (50.78)

$ (69.74)

Diluted (in USD per share)

^[1]

$ (50.78)

$ (69.74)

Weighted-average common shares outstanding:

Basic (in shares)

^[1]

1,476,247

1,387,632

Diluted (in shares)

^[1]

1,476,247

1,387,632

Product revenue, net

Revenues [Abstract]

Total revenue

^[1]

$ 15,523,000

$ 12,734,000

Other revenue

Revenues [Abstract]

Total revenue

^[1]

$ 250,000

$ 750,000

[1]	All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information
[2]	All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information

EIGR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

^[1]

$ 25,440

$ 25,798

Short-term debt securities

^[1]

73,150

Accounts receivable, net

^[1]

1,682

1,749

Inventories, net

^[1]

1,556

2,853

Prepaid expenses and other current assets

^[1]

9,161

13,985

Total current assets

^[1]

37,839

117,535

Property and equipment, net

^[1]

627

696

Other assets

^[1]

360

1,908

Total assets

^[1]

38,826

120,139

Current liabilities:

Accounts payable

^[1]

2,115

8,975

Accrued liabilities

^[1]

9,966

15,655

Current portion of operating lease liabilities

^[1]

491

Current portion of long-term debt

^[1]

41,119

Total current liabilities

^[1]

53,284

25,121

Debt, net

^[1]

39,625

Operating lease liabilities

^[1]

Total liabilities

^[1]

53,284

64,829

Commitments and contingencies (Note 12)

^[1]

Stockholders’ (deficit) equity:

Common stock, $0.001 par value, 200,000,000 shares authorized as of December 31, 2023 and 2022; 1,479,483 and 1,469,149 shares issued and outstanding as of December 31, 2023 and 2022, respectively

^[1]

Additional paid-in capital

^[1]

497,866

492,802

Accumulated other comprehensive loss

^[1]

(169)

(300)

Accumulated deficit

^[1]

(512,156)

(437,193)

Total stockholders’ (deficit) equity

^[1],[2]

(14,458)

55,310

Total liabilities and stockholders’ (deficit) equity

^[1]

$ 38,826

$ 120,139

[1]	All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information.
[2]	All periods presented have been retroactively adjusted to reflect the 1-for-30 reverse stock split effected on January 5, 2024. Refer to Note 1for further information

About Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

CEO	Dr. David Apelian M.B.A., M.D., MBA, Ph.D.
WEBSITE	eigerbio.com
INDUSTRY	Biotechnology
EMPLOYEES	56

Eiger BioPharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Eiger BioPharmaceuticals Inc? What does EIGR stand for in stocks?

EIGR is the stock ticker symbol of Eiger BioPharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eiger BioPharmaceuticals Inc (EIGR)?

As of Tue May 07 2024, market cap of Eiger BioPharmaceuticals Inc is 3.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EIGR stock?

You can check EIGR's fair value in chart for subscribers.

What is the fair value of EIGR stock?

You can check EIGR's fair value in chart for subscribers. The fair value of Eiger BioPharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eiger BioPharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EIGR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eiger BioPharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether EIGR is over valued or under valued. Whether Eiger BioPharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Eiger BioPharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EIGR.

What is Eiger BioPharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, EIGR's PE ratio (Price to Earnings) is -0.05 and Price to Sales (PS) ratio is 0.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EIGR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eiger BioPharmaceuticals Inc's stock?

In the past 10 years, Eiger BioPharmaceuticals Inc has provided -0.526 (multiply by 100 for percentage) rate of return.